The purpose of this study was to investigate the relationship between hepatic triglyceride content and both myocardial function and metabolism in type 2 diabetes mellitus (T2DM).
Background
Heart disease is the leading cause of mortality in T2DM. Central obesity and hepatic steatosis, both hallmark abnormalities in T2DM, have been related to increased risk of heart disease.
Methods
Sixty-one T2DM patients underwent myocardial perfusion and substrate metabolism measurements by positron emission tomography, using [ 15 O]water, [ 11 C]palmitate, and [
18 F]-2-fluoro-2-deoxy-D-glucose. In addition, wholebody insulin sensitivity (M/I) was determined. Myocardial left ventricular function and high-energy phosphate metabolism were measured using magnetic resonance imaging and [
31 P]-magnetic resonance spectroscopy, respectively. Hepatic triglyceride content was measured by proton magnetic resonance spectroscopy. Patients were divided according to hepatic triglyceride content (T2DM-low Յ5.56% vs. T2DM-high Ͼ5.56%).
Results
In addition to decreased M/I (p ϭ 0.002), T2DM-high patients had reduced myocardial perfusion (p ϭ 0.001), glucose uptake (p ϭ 0.005), and phosphocreatine/adenosine triphosphate (PCr/ATP) ratio (p ϭ 0.003), compared with T2DM-low patients, whereas cardiac fatty acid metabolism and left ventricular function were not different. Hepatic triglyceride content correlated inversely with M/I (Pearson's r ϭ Ϫ0.620, p Ͻ 0.001), myocardial glucose uptake (r ϭ Ϫ0.413, p ϭ 0.001), and PCr/ATP (r ϭ Ϫ0.442, p ϭ 0.027). Insulin sensitivity correlated positively with myocardial glucose uptake (r ϭ 0.528, p Ͻ 0.001) and borderline with myocardial PCr/ATP (r ϭ 0.367, p ϭ 0.072), whereas a positive association was found between cardiac glucose uptake and PCr/ATP (r ϭ 0.481, p ϭ 0.015).
Conclusions
High liver triglyceride content in T2DM was associated with decreased myocardial perfusion, glucose uptake, and high-energy phosphate metabolism in conjunction with impaired M/I. The long-term clinical implications of hepatic steatosis with respect to cardiac metabolism and function in the course of T2DM require further study. In the past few decades, the prevalence of obesity and type 2 diabetes mellitus (T2DM) has grown to epidemic proportions (1) . T2DM patients are at increased risk of cardiovascular disease (CVD), particularly coronary artery disease (CAD) and heart failure, and consequently, heart disease is the most common cause of death in T2DM (2, 3) . Cardiac abnormalities in T2DM patients can, however, develop in the absence of hypertension or CAD. These myocardial derangements are attributed to diabetic cardiomyopathy (4), a disease entity with a high propensity to progress into overt congestive heart failure (5). Several mechanisms have been proposed to underlie diabetic cardiomyopathy (4) , particularly, the metabolic hallmarks of the T2DM phenotype such as insulin resistance, dyslipidemia, and hyperglycemia. These diabetesrelated metabolic derangements are collectively thought to contribute to altered myocardial substrate handling and, subsequently, to the observed cardiac (diastolic) dysfunction (4) . The underlying mechanisms include oxidative stress, mitochondrial dysfunction, and compromised high-energy phosphate metabolism (4) .
Hepatic steatosis is a common finding in patients with (uncomplicated) T2DM. It is associated with a cluster of metabolic abnormalities, including insulin resistance, hyperglycemia, dyslipidemia, and a proinflammatory state, all factors known to adversely affect the cardiovascular system (6, 7) . Indeed, several studies in humans showed an association of fatty liver with an increased carotid intima media thickness (8) , impaired flowmediated vasodilation (9), advanced atherosclerosis (10) , and CVD/CAD (6) . Interestingly, high liver fat was associated with alterations in myocardial highenergy phosphate metabolism in healthy obese individuals (11) , and myocardial glucose metabolism in T2DM patients with CAD (12) . These studies have provided hypothesisgenerating preliminary data regarding the potential mechanisms that could link liver steatosis to cardiac disease as a risk factor for CVD. However, whether high liver fat adversely affects metabolic or functional aspects of the heart in asymptomatic patients with uncomplicated T2DM still remains to be determined.
Using state-of-the-art imaging techniques, the aim of the present study was to assess the relationship between liver triglyceride content and myocardial metabolism in T2DM patients with verified absence of clinical ischemic heart disease.
Methods
Participants. Sixty-one T2DM patients were selected from a previous study based on availability of positron emission tomography (PET) measurements (13) . This 2-center study was approved by the medical ethics committee of both centers and performed in compliance with the Declaration of Helsinki. All patients signed informed consent before inclusion. Patients were recruited by advertisements in local newspapers. Male T2DM patients, age 45 to 65 years, without diabetes-related complications were eligible. Inclusion criteria were a glycosylated hemoglobin level of 6.5% to 8.5% at screening, body mass index of 25 to 32 kg/m 2 , and blood pressure not exceeding 150/85 mm Hg (with or without the use of antihypertensive drugs). Patients were excluded if they had a history of or current hepatic disease or CVD and if they used insulin, fibrates, thiazolidinediones, or other hormonal replacement therapy. Screening of patients consisted of medical history, physical examination, echocardiogram, and fasting blood and urine analyses. In addition, patients underwent dobutamine-stress echocardiography to confirm absence of inducible ischemia. After successful screening, participants commenced with a 10-week run-in period during which their regular blood glucose-lowering agents were changed to glimepiride monotherapy and titrated until a stable dose was reached during the 8 weeks before assessments to exclude possible confounding effects on myocardial metabolism of differential agents. The present baseline data were derived from a previously reported intervention study (13) , in which participants were randomized to pioglitazone or metformin after baseline measurements to study the effects of these agents on cardiac function and metabolism. Imaging. The study protocol was performed during 2 visits within the same week. During 1 visit, cardiac perfusion and substrate metabolism were measured using PET, and during the other visit, myocardial function was measured by magnetic resonance imaging and hepatic triglyceride content and myocardial phosphate creatine/adenosine triphosphate (PCr/ATP) ratio by proton magnetic resonance spectroscopy and phosphorus- 31 (17) . Because resting myocardial perfusion is related to the rate-pressure product (RPP) (RPP ϭ heart rate ϫ systolic blood pressure), corrected resting MBF (1,000 ϫ MBF/RPP) was also calculated (18) . Moreover, myocardial vascular resistance was calculated by dividing the mean arterial pressure by myocardial rest perfusion (18) . [ 11 C]palmitate time-activity curves were analyzed using a 3-tissue plasma input kinetic model, which, together with plasma nonesterified fatty acid concentrations, enabled calculation of myocardial fatty acid uptake, oxidation, and esterification (myocardial fatty acid uptake, myocardial fatty acid oxidation, and myocardial fatty acid esterification, respectively) (13, 19) . The [ 11 C]palmitate image-derived input function was corrected for [
11 C]CO 2 metabolites and differences between plasma and whole blood concentrations as described elsewhere (13, 19) . MMRglu was calculated by multiplying the net influx constant for [ 18 F]FDG, K i , by the mean plasma glucose concentration. For determination of K i , Patlak graphic analysis was used (20) . Magnetic resonance imaging. The heart was imaged in short-axis orientation using electrocardiographically gated breath holds with a sensitivity-encoding balanced turbofield echo sequence. LV ejection fraction, cardiac output, stroke volume, LV end-diastolic volume, and LV endsystolic volume, LV mass, and their indexes calculated by dividing each parameter through the body surface area (cardiac index, LV end-diastolic volume index, LV endsystolic volume index, and LV mass index), were determined by analyses of end-diastolic and -systolic images (21) . An electrocardiographically gated gradient-echo sequence with velocity encoding was performed to measure blood flow across the mitral valve to determine LV diastolic function. Measures included the peak filling rate of the early filling phase (E) and of the atrial contraction (A), the ratio of the peak filling rates (E/A), and the peak deceleration gradient of the early filling phase (E deceleration peak). Additionally, an estimation of LV filling pressure (E/Ea) was calculated (22) . During magnetic resonance imaging, blood pressure and heart rate were measured.
To quantify the amount of visceral and subcutaneous abdominal fat, 3 consecutive transverse images were obtained during 1 breath hold with the middle image at a level just above the fifth lumbar vertebra (23) . All images were analyzed quantitatively using dedicated software (FLOW or MASS, Medis, Leiden, the Netherlands). Hepatic proton magnetic resonance spectroscopy. Hepatic proton magnetic resonance spectroscopy was performed as described previously (21, 24) . Briefly, to obtain hepatic proton magnetic resonance spectra, an 8-ml voxel was positioned in the liver, avoiding gross vascular structures and adipose tissue depots. Both spectra with and without water suppression were obtained to calculate hepatic triglyceride content as a percentage relative to water (100 ϫ triglyceride/water) (24) . To quantify hepatic triglyceride content, the methylene and water signals were corrected for T 2 decay by use of the exponential relaxation equation: S c ϭ S 0 exp(ϪTE/T 2 ), where S c represents the corrected signal; TE, the echo time; T 2 , the longitudinal relaxation time; and S 0 the signal after application of the 90°pulse. T 2 relaxation times for water and triglyceride of 50 and 60 ms, respectively, were used as described by Szczepaniak et al. (24) . A fatty liver was defined as hepatic triglyceride content exceeding 5.56% (24, 25) . Myocardial proton magnetic resonance spectroscopy. Electrocardiographically triggered [ 31 P]-MR spectra of the LV anterior wall were acquired using a 100-mm diameter surface coil. Volumes of interest were selected by imageguided spectroscopy with 3-dimensional in-situ storage image sensor. Shimming was performed automatically and tuning and matching of the [ 31 P] surface coil was performed manually. Spectroscopic volume size typically was 7 ϫ 7 ϫ 7 cm. Acquisitions were based on 192 averaged free induction decays, and total acquisition time was 10 min. [ 31 P]-MR spectra were corrected for partial saturation effects and for the ATP contribution from blood in the cardiac chambers. The myocardial PCr/ATP ratios of the spectra were calculated and used as a parameter representing myocardial high-energy phosphate metabolism (26, 27) . Biochemical analyses. Samples were analyzed at 1 certified central laboratory (Amsterdam, the Netherlands). Glycosylated hemoglobin was determined by high-performance liquid chromatography (Menarini Diagnostics, Florence, Italy) (reference values: 4.3% to 6.1%). Plasma glucose was quantified by the use of a hexokinase-based technique (Roche Diagnostics, Mannheim, Germany). Plasma triglycerides, total cholesterol, and high-density lipoprotein cholesterol were determined using enzymatic colorimetric methods (Modular, Hitachi, Japan). Levels of low-density lipoprotein cholesterol were calculated using Friedewald's Comparisons between groups were made using independent t tests. Linear regression was used to adjust for body mass index differences between groups. The chi-square test was used for nominal parameters. Univariate and multiple analyses with a forward selection procedure were performed. The aim of these analyses was to determine which variables influence liver triglyceride content, MMRglu, and PCr/ ATP. Those variables with p Ͻ 0.1 were subsequently entered in a forward multivariable regression analysis and those variables with p Ͻ 0.05 were considered independently related to the dependent variable. As liver triglyceride content was a skewed variable, this variable was logtransformed. Moreover, several independent variables were log-transformed. Analyses were performed with SPSS software version 15.0 (SPSS Inc., Chicago, Illinois). A 2-tailed probability value Ͻ0.05 was considered significant. Table 1 shows characteristics of the entire study population, divided into groups with high and low hepatic triglyceride content. Both groups did not differ with respect to age, glycemic control, duration of diabetes, and use of medication. Body mass index and plasma triglycerides, however, were higher in the T2DM-high group. Metabolic characteristics are given in Table 2 , showing higher fasting plasma insulin and lactate and a borderline significant increase in C-reactive protein in T2DM-high patients. Under hyperinsulinemic euglycemic clamp conditions, plasma fatty acid, and insulin levels were higher and M/I was lower in T2DM-high patients. No differences were observed in myocardial hemodynamics, and LV systolic and diastolic function and dimensions between T2DM-high and T2DM-low patients (Table 3) . Myocardial perfusion and metabolism. MBF was lower in T2DM-high than in T2DM-low patients (Fig. 1A) , also after correction for rate-pressure product (1.07 Ϯ 0.04 vs. (Fig. 1B) and the PCr/ATP ratio (Fig. 1C) Table 4 , revealing M/I and visceral fat volume to be independently related to liver triglyceride content, plasma fatty acid and lactate levels to be independently related to MMRglu, and only MMRglu to be independently related to PCr/ATP. Among others, significant associations were seen between both myocardial glucose and fatty acid metabolism and plasma levels of malondialdehyde. Correlations between liver triglyceride content, MMRglu, and myocardial PCr/ATP ratio are shown in Figure 2 .
Results

Assessment
Discussion
In the present study, reduced myocardial perfusion, glucose uptake, and PCr/ATP ratio were found in T2DM patients with high liver triglyceride content with verified absence of inducible ischemia. LV function and dimensions, however, were similar to those of T2DM patients with low liver Data are mean Ϯ SE or median (interquartile range).
Biochemical and Metabolic Characteristics of the Study Population
A ϭ diastolic atrial contraction; E ϭ early diastolic filling phase; E/Ea ϭ estimate of the left ventricular filling pressure; LV ϭ left ventricular; other abbreviations as in Table 1 .
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Hepatic Triglyceride Content Affects Myocardial Metabolism triglyceride content. Moreover, liver triglyceride content was inversely associated with myocardial substrate and high-energy phosphate metabolism. Furthermore, to the best of our knowledge, this study is the first to show a direct positive relationship between myocardial glucose metabolism and levels of myocardial PCr/ATP in human T2DM in vivo. In the present study, T2DM patients with increased liver triglyceride content were characterized by lower highdensity lipoprotein cholesterol, higher plasma triglyceride and C-reactive protein levels, and lower insulin sensitivity compared with T2DM patient with low liver triglyceride content. None of the patients had CVD or diabetes-related complications, allowing the assessment of early myocardial abnormalities in the absence of potentially confounding effects of CAD and hypertension. Myocardial glucose uptake was decreased in T2DM patients with high versus low liver triglyceride content, confirming previous data from Lautamaki et al. (12) , who reported decreased PET-measured myocardial glucose consumption in nonstenotic myocardial segments of T2DM patients with CAD and high liver triglyceride content. In the present study, plasma fatty acid levels were inversely related to myocardial glucose metabolism; therefore, increased substrate levels may explain reduced myocardial glucose metabolism by reverse substrate competition. A more pronounced impairment of insulin signaling and reduced membrane-bound glucose transporter-4 in T2DM patients with high liver triglyceride content, however, may also have contributed to decreased myocardial glucose metabolism (29, 30) .
Decreased resting myocardial perfusion and increased myocardial vascular resistance, observed in the present study, may indicate an early alteration in myocardial tissue and/or vascular properties in T2DM patients with high liver triglyceride content. Although age, sex, and RPP are known to influence resting myocardial perfusion (31), these were similar in the 2 groups and therefore cannot explain the differences in myocardial perfusion between both groups. Induced hyperinsulinemia has been shown to significantly increase myocardial perfusion at rest in T2DM patients with CAD, also in nonaffected cardiac regions, emphasizing the role of insulin action on myocardial perfusion (32) . The observed difference in myocardial perfusion between both groups in the present study may be related to the same mechanism because T2DM patients with high liver triglyceride content were significantly more insulin resistant. Previously, resting myocardial perfusion under hyperinsulinemia in nonstenotic cardiac segments was not different in T2DM patients with high versus low liver triglyceride content and CAD, whereas myocardial glucose uptake was lower in patients with high liver triglyceride content (12) . Because myocardial perfusion and glucose metabolism were measured under fasting and hyperinsulinemic conditions, respectively, the present study design does not allow direct comparisons. Nevertheless, it is likely that the relatively small decrease in myocardial perfusion is responsible for only a minor fraction of the decrease in myocardial glucose metabolism in the T2DM patients with high liver triglyceride content. The major fraction of this decrease presumably is an intrinsic effect or related to substrate competition as mentioned previously. *For those independent variables, the regression coefficient is estimated for a difference of 1 U in the log of the independent variable. The transformed regression coefficient can be interpreted as follows: A difference of 1 unit log HbA 1c is related to a 1.318 ϫ higher liver triglyceride content. †MMRglu was significantly related to MFAU (p ϭ 0.010) and MFAO (p ϭ 0.009) in those patients for whom PCr/ATP data were available. HbA 1c ϭ glycosylated hemoglobin; M/I value ϭ whole-body insulin sensitivity adjusted during steady state; MFAO ϭ myocardial fatty acid oxidation; MFAU ϭ myocardial fatty acid uptake; MMRglu ϭ myocardial metabolic rate of glucose uptake; other abbreviations as in Tables 1 and 2 .
High liver triglyceride content in T2DM patients was also associated with a decreased myocardial PCr/ATP ratio. Myocardial PCr/ATP is known to be decreased in a variety of diseases, obesity and T2DM, among others (33) (34) (35) . The present results in T2DM patients with verified absence of inducible ischemia are in line with those of a previous study by Perseghin et al. (11) , who reported a reduced myocardial PCr/ATP ratio in young nondiabetic men with high versus low liver triglyceride content. Fatty acids, glucose, and lactate are the primary energy substrates of the heart, with a substrate preference depending on myocardial workload and substrate supply in conjunction with feeding status (36) . Glucose, however, is the most energy-efficient substrate (36) . Experimental data suggest that increased fatty acids relative to glucose metabolism lead to the formation of toxic lipid-signaling molecules and oxidative stress, ultimately resulting in mitochondrial dysfunction and reduced ATP synthesis (4, 37) . In the present study, inverse relationships between myocardial glucose and fatty acid metabolism and plasma levels of malondialdehyde were found. Moreover, a positive relationship between myocardial glucose metabolism and myocardial PCr/ATP ratio was found in T2DM patients. The present study design precludes an assessment of whether those associations describe a cause-and-effect relationship. It may, however, be speculated that when glucose relative to fatty acid metabolism contributes more to total ATP synthesis, this may result in a more favorable myocardial energy level.
Although myocardial metabolism differed between T2DM patients with high and low liver triglyceride content, no such differences were seen in myocardial systolic and diastolic function or dimensions. This finding corresponds to the earlier work of Perseghin et al. (11) , who found differences in PCr/ATP ratios, but not in myocardial function and dimensions between nondiabetic men with high compared with those with low liver triglyceride content. Study limitations. The following limitations need to be considered in the present study. First, PET measurements were performed under different conditions (i.e., fasting perfusion and fatty acid measurements, but euglycemic hyperinsulinemic clamp conditions for measurement of glucose metabolism). A euglycemic hyperinsulinemic clamp is mandatory because under fasting conditions, virtually no glucose metabolism will be present in insulin-resistant myocardium. Differences in myocardial perfusion and glucose metabolism in the 2 groups are therefore not readily interpretable. Second, there were substantially fewer myocardial PCr/ATP data available than for the other measurements. Third, only men were included, which limits generalizability of the results to both sexes.
Conclusions
In the absence of diabetes-related complications and inducible ischemia, T2DM patients with high liver triglyceride content showed decreased myocardial perfusion, glucose uptake, high-energy phosphate metabolism, and wholebody insulin resistance compared with similar patients with low liver triglyceride content. The long-term clinical implications of this association between liver steatosis and altered cardiac metabolism require further study in T2DM. Correlation between liver triglyceride content and myocardial metabolic rate of glucose (MMRglu) (A), between liver triglyceride content and myocardial phosphocreatine/adenosine triphosphate (PCr/ATP) ratio (B), and between MMRglu and myocardial PCr/ATP (C) in those type 2 diabetes mellitus (T2DM) patients in whom myocardial PCr/ATP data were available.
